Table 3.
Comparison between ER81 expression and clinical data in breast cancers.
| n | ER81 negative (%) | ER81 positive (n, %)* | P (χ 2) | |
|---|---|---|---|---|
| Age, years | ||||
| ≤50 | 48 | 22 (45.8) | 26 (54.2) | .814 |
| >50 | 33 | 16 (48.5) | 17 (51.5) | |
| Menopause | ||||
| Before | 46 | 22 (47.8) | 24 (52.2) | .483 |
| After | 35 | 14 (40.0) | 21 (60.0) | |
| Tumor size, cm | ||||
| ≤2 | 15 | 7 (46.7) | 8 (53.3) | .138 |
| 2–5 | 55 | 28 (50.9) | 27 (49.1) | |
| >5 | 11 | 2 (18.2) | 9 (81.8) | |
| Nodal status | ||||
| Negative | 43 | 18 (41.9) | 25 (58.1) | .463 |
| Positive | 38 | 19 (50.0) | 19 (50.0) | |
| Histological stage | ||||
| I | 10 | 6 (60.0) | 4 (40.0) | .246 |
| II | 54 | 14 (25.9) | 30 (74.1) | |
| III | 17 | 6 (35.3) | 11 (64.7) | |
| ER | ||||
| Negative | 25 | 1 (4.0) | 24 (96.0) | .001 |
| Positive | 56 | 22 (39.3) | 34 (60.7) | |
| PR | ||||
| Negative | 28 | 3 (10.7) | 25 (89.3) | .010 |
| Positive | 53 | 20 (37.7) | 33 (62.3) | |
| HER2 amplification | ||||
| Negative | 53 | 19 (35.8) | 34 (64.2) | .041 |
| Positive | 28 | 4 (14.3) | 24 (85.7) |
*Breast cancer tissues with IRS ≥ 3 were considered as ER81 positive expression.